Our growing presence in Japan and the Asia-Pacific region
Dr Rebecca Lew, PhD, CMPP, of ProScribe, part of the Envision Pharma Group delivered the “Best of ISMPP” session at the recent ISMPP Country Champions Meetings in Tokyo on November 21 and in Singapore on November 25
Dr Rebecca Lew, PhD, CMPP, of ProScribe, part of the Envision Pharma Group delivered the “Best of ISMPP” session at the recent ISMPP Country Champions Meetings in Tokyo on November 21 and in Singapore on November 25. These meetings were a mixture of presentations and roundtable discussions designed to increase the awareness of the Good Publications Practice Guidelines (GPP3) in the Asia Pacific region and the practicalities of their implementation – a full agenda of the topics covered is available here.
Dr Lew’s presentation summarized the key takeaways from the 2016 ISMPP Annual Meeting and customized them for the Asia Pacific region. The Country Champion events bridge the information gap between the inaugural Asia Pacific Meeting of ISMPP in 2015 and the next iteration of this biennial meeting (Tokyo, September 5, 2017).
As awareness of GPP3 grows in the Asia-Pacific region, the need for compliant, technology-enabled, medical writing support is increasing. Consequently, Envision is delighted to announce that the ProScribe leadership team, Professor Karen Woolley, PhD, CMPP, and Mark Woolley, PhD, will be relocating to Tokyo to drive the expansion of our Japan team and enhance the range of services we provide in the region. Professor Karen Woolley is a renowned expert in the delivery of compliant publication programs, particularly in the Asia Pacific region, and is an author on the GPP3 Guidelines published in the Annals of Internal Medicine. A translation of this publication is now available in Chinese, with a Japanese translation coming soon.
In the near future, we will be bolstering our current writing and client solutions team in the Tokyo office with Japanese-language customer care support for Datavision® and our other technology solutions.
Datavision® is the industry-standard, purpose-built publication-planning software solution, developed and maintained by The Envision Pharma Group for the management of global publication plans. It is currently used by more than 60 pharma and medical device companies to ensure consistent operating practices across international boundaries. Datavision® manages the various publication-related activities of more than 35,000 registered users across these global clients, their affiliates, their supporting agencies and external authors.
Please visit our website for more information on our full range of Medical Affairs services, our industry-leading software solutions, including Datavision®, Visiontracker®, Visiontracker HEORTM, MedinfoTM, Clear®, and LibraryTM.